Biotech News

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen (PEPG)PepGen2026-05-12 20:05 ESTEarnings

– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort – – The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 – – Well-funded with $132.3M of cash as

PepGen

Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2...

Recent company news

PEPGPepGen2026-08-06 11:32 EST

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PEPGPepGen2026-08-06 11:30 EST

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PEPGPepGen2026-05-21 11:00 EST

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

PEPGPepGen2026-05-12 20:05 EST